Compare CHMI & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHMI | MXCT |
|---|---|---|
| Founded | 2012 | 1999 |
| Country | United States | United States |
| Employees | 14 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.0M | 93.0M |
| IPO Year | N/A | 2021 |
| Metric | CHMI | MXCT |
|---|---|---|
| Price | $2.60 | $0.86 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 4 |
| Target Price | $3.00 | ★ $5.50 |
| AVG Volume (30 Days) | 188.8K | ★ 865.9K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 15.50% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $33,026,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $61.13 | $18.50 |
| P/E Ratio | $139.30 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.17 | $0.64 |
| 52 Week High | $3.14 | $2.96 |
| Indicator | CHMI | MXCT |
|---|---|---|
| Relative Strength Index (RSI) | 45.29 | 57.55 |
| Support Level | $2.50 | $0.65 |
| Resistance Level | $2.76 | $0.88 |
| Average True Range (ATR) | 0.05 | 0.05 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 31.25 | 82.54 |
Cherry Hill Mortgage Investment Corp is a fully integrated, internally managed residential real estate finance company focused on acquiring, investing in and managing residential mortgage assets in the United States. It invests in residential mortgage assets to generate current yields and risk-adjusted total returns for its stockholders over the long term, through dividend distributions and secondarily through capital appreciation. The company's reportable segments include investments in Residential mortgage-backed securities (RMBS), Investments in Servicing Related Assets, and All Others. It generates maximum revenue from the RMBS segment in the form of Interest income earned for servicing mortgage loans.
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.